Savara (SVRA) is back in focus after announcing that Chief Financial and Administrative Officer Dave Lowrance will step down for health reasons. Chief Operating Officer Robert Lutz will take on the additional CFO role.

Savara’s share price return has cooled in recent months, with the stock down 6.7% year to date despite a very large 1 year total shareholder return of 138%, as investors weigh recent leadership changes and the prior authorization to issue more shares.

If this kind of volatility has your attention, it can be helpful to widen the lens and see what else is moving. You can start with 40 healthcare AI stocks.

With the stock trading at $5.26 and a very large gap to the average analyst price target of $10.94, yet no revenue and ongoing losses, should you view Savara as undervalued, or is the market already incorporating expectations for future growth into the price?

Preferred Price to Book Multiple of 7.6x: Is it justified?

Savara trades on a P/B of 7.6x, which sits well above both its biotech peers and the broader US Biotechs industry, setting a high bar for expectations at the current $5.26 share price.

P/B compares a company’s market value with its net assets on the balance sheet and is often used for early stage or loss making stocks where earnings based ratios are less useful. For Savara, with no revenue and a reported net loss of $129.482m, this multiple reflects what investors are currently willing to pay for its clinical pipeline and future potential rather than current financial performance.

In that context, the data points to a rich valuation. Savara is described as expensive on a 7.6x P/B compared with both the US Biotechs industry average of 2.4x and a peer average of 5.2x. With no meaningful revenue yet and ongoing losses, the current multiple indicates that the market is already assigning a high value to its rare respiratory disease program and associated prospects.

Result: Price-to-book ratio of 7.6x (OVERVALUED)

However, there are clear risks, including ongoing losses of $129.482m with no current revenue and potential dilution pressure from any future share issuance.

Next Steps

With mixed signals around valuation, risk and potential, it makes sense to look at the full picture yourself and move quickly while sentiment is still split. To see how those concerns stack up against the possible upside, review the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Savara has you thinking about risk, reward and timing, do not stop here. Use targeted stock lists to uncover fresh ideas that better fit your goals.

• Zero in on potential bargains by scanning companies flagged as 44 high quality undervalued stocks and compare their fundamentals with what you see in Savara.
• Prioritise resilience by reviewing 71 resilient stocks with low risk scores that score well on business quality and balance sheet strength.
• Get ahead of the crowd by tracking a screener containing 20 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.